NASDAQ$PROK
ProKidney Corp · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Reported business updates and financial results for the second quarter ended June 30, 2024
ProKidney reported positive interim REGEN-007 data, restarted manufacturing, resumed PROACT 1 and PROACT 2 Phase 3 trials, and closed a $140 million equity offering. The company ended the quarter with $431.5 million in cash and cash equivalents and marketable securities.
- Reported interim REGEN-007 data demonstrating rilparencel’s potential to preserve kidney function in patients with diabetes and advanced CKD
- Restarted manufacturing and resumed PROACT 1 and PROACT 2 Phase 3 trials
- Closed $140 million upsized underwritten public offering and concurrent registered direct offering
- Ended the second quarter with $431.5 million in cash and cash equivalents and marketable securities, supporting operations through projected Phase 3 enrollment completion in mid-2026
Headline financials
Revenue & EPS history
ProKidney · Revenue · Quarterly
$0
Forward guidance
ProKidney expects that its existing cash, cash equivalents and marketable securities held on June 30, 2024, will enable it to fund its operating expenses and capital expenditure requirements into mid-2026.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 15 quarterly earnings reports · overlaid with Q2 2024
-2.4%
Avg return
Earnings day
-3.0%
Avg return
5 days after
+2.6%
Avg return
30 days after
25%
4 / 16 earnings
Positive
+18.0%
Q1 2024
Best reaction
-13.1%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.3% | -1.2% | -4.7% | |
| Q4 2025 | -4.0% | -8.9% | +2.3% | |
| Q3 2025 | -8.8% | -16.6% | -24.9% | |
| Q2 2025 | -0.9% | +4.7% | +32.2% | |
| Q1 2025 | -6.0% | -9.3% | -1.4% | |
| Q4 2024 | -6.8% | -7.7% | -23.9% | |
| Q3 2024 | -3.7% | -21.2% | -12.6% | |
| Q2 2024 | -0.5% | +9.1% | +11.5% | |
| Q1 2024 | +18.0% | +50.2% | +22.2% | |
| Q4 2023 | -4.1% | +8.9% | +39.7% | |
| Q3 2023 | -13.1% | -24.4% | +20.0% | |
| Q2 2023 | +0.4% | -14.5% | -37.5% | |
| Q1 2023 | +1.2% | +8.1% | +34.0% | |
| Q4 2022 | -9.8% | -12.9% | -24.6% | |
| Q3 2022 | -4.7% | -14.8% | -23.6% | |
| Q2 2022 | +7.3% | +2.7% | +32.6% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro